Companies › O&D BioTech Group
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Mar 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| O&D-001 injection Chimeric antigen receptor T cell targeting BCMA and GPRC5D | BCMA, GPRC5D | Phase 1 | Relapsed or Refractory Multiple Myeloma | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07369895 | O&D-001 injection | Phase 1 | Relapsed or Refractory Multiple Myeloma | Oncology | Mar 2028 |
Johnson & Johnson (Janssen) Regeneron Pharmaceuticals iCell Gene Therapeutics Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical AbbVie Chongqing Precision Biotech Poseida Therapeutics AstraZeneca Lakefront Biotherapeutics West Gracell Biotechnologies (Shanghai)
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.